News

The Oriental Congress of Cardiology 2012 Held in Shanghai

The 6th Oriental Congress of Cardiology (OCC 2012) was held at Shanghai International Convention Center from May 25 to 27, 2012.
On May 23, MicroPort organized the "2012 Cardiac Intervention Device and Clinical Technology Development Summit" in Ritz Carton Hotel, Shanghai. MicroPort invited many national renowned experts in cardiac intervention field, including academician Junbo Ge from Zhong Shan Hospital Fudan University, chief doctor Weiyi Fang from Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University, chief doctor Haichang Wang from Xijing Hospital, Zuyi Yuan, the director of the First Affiliated Hospital of Medical College of Xian Jiaotong University, chief doctor Zhangzheng from the First Affiliated Hospital of Lanzhou University, and chief doctor Zhizhong Li from Beijing Anzhen Hospital to attend the summit.
On May 26, MicroPort organized a satellite meeting on the theme of 2-year follow-up of Firebird2 clinical studies. Chief doctor Yundai Chen from 301 Hospital, chief doctor Huiliang Liu from the Armed Police General Hospital, chief doctor Yingzhong Lin from the People’s Hospital of Guangxi Zhuang Autonomous Region, chief doctor Juying Qian from Zhong Shan Hospital Fudan University, and chief doctor Dadong Zhang from Shanghai Minhang Hospital were invited to be co-chairmen. The chief doctor Zhangfeng presented the results in regard to the 2-year follow-up clinical studies named "FOCUS". The follow-up rate reached 95.7%. Among 4867 enrolled patients, the All Death ratio was 2.51%. The MACE (Major Adverse Cardiac Events) was 5.2% which includes 1.52% of cardiac-related death, Q-wave myocardial infarction 1.23%, and non-Q-wave myocardial infarction 2.03%. The incidence of TVR and thrombosis was 1.58% and 1.5% respectively. Doctor Zesheng Xu, Doctor Lin Wang, and Doctor Yongjian Yang also presented relevant case studies from other participated research centers. The optimized vessel conformability, low incidence of restenosis and thrombosis has been recognized by many experts, and all of these results have further validated the efficacy and safety of Firebird2.